AUTHORS
Yu Kang, MD, PhD, Sneha Sharma, DO2, Qiuhong Zhao, MS3, Aseel Alsouqi, MD4, Amneet Kaur Bajwa, MD5, Tyler Everhardt, PharmD6, Kerry A. Rogers, MD7, Tracy Wiczer, PharmD8, Jennifer A. Woyach, MD9, Adam Ali Potter, MD10, Seema Ali Bhat, MD11
AFFILIATIONS
1 The Ohio State University, Columbus, Ohio, United States
2 The Ohio State University, Columbus, Ohio, United States
3 The Ohio State University, Columbus, Ohio, United States
4 The Ohio State University, Columbus, Ohio, United States
5 The Ohio State University, Columbus, Ohio, United States
6 The Ohio State University, Columbus, Ohio, United States
7 The Ohio State University, Columbus, Ohio, United States
8 The Ohio State University, Columbus, Ohio, United States
9 The Ohio State University, Columbus, Ohio, United States
10 The Ohio State University, Columbus, Ohio, United States
11 The Ohio State University, Columbus, Ohio, United States
ABSTRACT
INTRODUCTION
Pirtobrutinib, a highly selective, non-covalent Bruton tyrosine kinase inhibitor (BTKi), has demonstrated efficacy and a favorable safety profile in patients previously treated with covalent BTK inhibitors. In the BRUIN-CLL-314 trial, which directly compared pirtobrutinib with ibrutinib, pirtobrutinib was associated with significantly lower rates of cardiovascular (CV) adverse effects like atrial fibrillation/flutter and hypertension. (Woyach et al. JCO 2026). However, real-world data on CV safety of pirtobrutinib remain limited. Therefore, we sought to characterize the incidence of major adverse cardiovascular events (MACE) among patients treated with pirtobrutinib at our institution.
METHODS
All consecutive adult patients who received either investigational or commercially available pirtobrutinib at The Ohio State University Comprehensive Cancer Center between December 2019 and September 2025 were included. Major adverse cardiovascular (CV) events (MACE) were defined as CV death, new-onset atrial fibrillation/flutter, acute coronary syndrome, new-onset myocarditis, new-onset pericarditis, ischemic or hemorrhagic stroke, uncontrolled hypertension, symptomatic heart failure, and asymptomatic left ventricular systolic dysfunction. All MACE were adjudicated according to the American College of Cardiology/American Heart Association (ACC/AHA) standardized CV outcome definitions for clinical trials (Hicks et al. JACC 2015). The cumulative incidence of MACE was estimated using non-CV death as a competing risk.
RESULTS
A total of 111 patients were included, of whom 89 (80.2%) had chronic lymphocytic leukemia and 22 (19.8%) had lymphoma. Median age at pitobrutinib treatment was 71 years (IQR: 65-77 years); 73 were male (65.8%). Eighty-one patients (73.0%) had a history of CV disease or CV risk factors, including hypertension (28.8%), hypercholesterolemia (40.5%), diabetes mellitus (12.6%), coronary artery disease (13.5%), atrial fibrillation/flutter (12.6%), heart failure (10.8%), and cerebrovascular disease (0.9%).
The median duration of pirtobrutinib treatment was 16 months (IQR, 8-24 months). Over a median follow-up of 18 months (range, 0.5-75 months; IQR, 9-31 months), 5 patients experienced a MACE. All 5 had pre-existing cardiovascular risk factors, including hypertension, hypercholesterolemia, and/or diabetes mellitus. Among these patients, 2 had a history of coronary artery disease and 1 had atrial fibrillation. These events included 1 each of non-ST-elevation myocardial infarction accompanied by new-onset atrial fibrillation, new-onset symptomatic heart failure with reduced ejection fraction (HFrEF) and atrial fibrillation, symptomatic HFrEF associated with severe aortic stenosis (previously undiagnosed prior to pirtobrutinib treatment), new-onset symptomatic HFrEF in the setting of sepsis, and new-onset atrial fibrillation associated with acute cerebrovascular disease.
The median time from initiation of pirtobrutinib to MACE was 25 months (range, 2-40 months; IQR, 23-31 months), with most events (4 of 5 [80%]) occurring close to or more than 2 years after treatment initiation. The median duration of pirtobrutinib therapy among patients who experienced MACE was 24 months (IQR, 9-34 months). Pirtobrutinib was discontinued in 3 of the 5 patients following MACE.
Among patients who experienced MACE, 3 of 5 (60%) died during index hospitalization, whereas the remaining 2 patients subsequently died from non-CV causes. The cumulative incidence of MACE, accounting for non-CV death as a competing risk, was 0.9% (95% CI, 0.1%-4.5%) at 1 year and 2.7% (95% CI, 0.5%-8.8%) at 2 years.
CONCLUSION
Pirtobrutinib therapy demonstrated a favorable CV safety profile, with a 2-year cumulative incidence of MACE of approximately 3%. Although the majority of MACE consisted of new-onset atrial fibrillation, we also observed a small number of cases of symptomatic heart failure. Our findings suggest that heart failure, although uncommon, remains a potential CV complication that warrants clinical vigilance during pirtobrutinib therapy. Coexisting CV risk factors may play a contributory role in the occurrence of these events.
DISCLOSURES
Yu Kang, MD, PhD: No relevant conflicts of interest to declare.